What are the rules on peptides and GLP-1s in the Netherlands, Belgium and Luxembourg?

The short answer

Three small, closely-linked countries, and the interesting divergence is not about import quantities. It is that Belgium restricted who may prescribe a GLP-1 by Royal Decree, requiring an endocrinologist for the first prescription — an instrument with no equivalent anywhere else in Europe that we found. The Netherlands reimburses liraglutide for obesity but not semaglutide. And Luxembourg's doping offence, unusually, requires an intention that someone else use the substance, so a reader assuming "Luxembourg has a doping law, therefore possession is a crime" would be wrong.

None of the three criminalises simple possession of a doping substance for personal use.

Evidence tier: Tier 1 for statutes and regulator guidance we read directly; several Belgian reimbursement pages are JavaScript-rendered and those items are marked. Educational content, not medical or legal advice.

The key points:

• Belgium regulated GLP-1 prescribing by Royal Decree, and may have let it lapse — verify before relying on it.
• The Netherlands reimburses Saxenda for obesity, not Wegovy, under strict conditions.
• Belgium's refusal of Wegovy cited the Dutch, German, Norwegian and Danish refusals — regulators are reasoning from each other.
• The Dutch inspectorate has said in terms that RUO disclaimers are an attempt to evade the law.
• Luxembourg's doping offence needs third-party purpose, so it does not reach personal possession.

Belgium did something no other European country did

Evidence tier: 1 for the instrument; its current status is unverified.

Belgium restricted GLP-1 prescribing by Royal Decree — requiring an endocrinologist for the first prescription, and banning officinal preparations containing semaglutide and tirzepatide. That is a regulatory instrument aimed at the prescriber rather than the patient or the importer, and we found no comparable measure in any other country in this series.

It appears to have lapsed on 30 November 2025. We could not confirm whether it was extended, and this is the sort of fact that determines whether a reader can actually get a prescription. Treat it as a live question rather than settled law.

Belgium then went further than anyone else on the reimbursement side. From 1 February 2026, a prior authorisation from the sickness fund is reportedly required for diabetes GLP-1s, so a prescription alone no longer suffices. The date and mechanism come from reporting rather than the primary instrument — RIZIV/INAMI pages are JavaScript-rendered and we could not open them — so this is unverified and flagged accordingly.

On obesity reimbursement, Belgium refused Wegovy on 3 June 2026, following negative advice from the CTG. The reasoning is worth noting because of what it cites: the Minister expressly invoked the Dutch Zorginstituut, Germany, Norway and Denmark. European regulators are not reaching these decisions independently — they are reading each other, and reasoning from the same two points: that the effect disappears on discontinuation, and that reimbursing one product sets a class-wide budget precedent.

The Netherlands reimburses the older drug

Evidence tier: 1 — enacted reimbursement conditions.

The Dutch position is counterintuitive and widely misreported.

Liraglutide (Saxenda) is reimbursed for obesity under strict conditions in Annex 2 of the Regeling zorgverzekering: a failed combined lifestyle intervention after one year, BMI ≥35 with comorbidity or BMI ≥40, and treatment stops at three months if less than 5% weight loss has been achieved.

Semaglutide (Wegovy) is not. It was refused in July 2024 and was still unassessed as of 21 July 2026.

Commercial sites claiming Wegovy entered the Dutch reimbursement system in April 2024 are wrong. If you are reading a page that says otherwise, check its date and its source.

The Dutch inspectorate has also been unusually direct about research-use labelling. IGJ, 16 April 2026: sellers "proberen de wet te omzeilen door het gebruik van disclaimers als 'voor onderzoeksdoeleinden', 'research chemicals', 'niet voor menselijke consumptie'… Toch promoten ze deze middelen actief." — they try to circumvent the law using disclaimers while actively promoting the products.

That is a regulator stating that the disclaimer is understood as evasion rather than accepted as a limitation. It matches what the FDA did in its August 2026 warning letters, which we covered in our analysis of those letters, and it is the same conclusion reached by regulators in Slovenia and Croatia.

Possession is not criminalised — but read Luxembourg carefully

Evidence tier: 1–2 — statutes read directly for Luxembourg and Belgium.

None of the three criminalises simple possession of a doping substance for personal use. That places Benelux on the opposite side of the line from Denmark, Norway and Sweden, where possession itself is an offence.

Luxembourg's provision is the one worth understanding, because its shape is unusual. Article 16 of the law of 3 August 2005 requires both that the substance be intended for use by a third party and that the holder knows it is for sporting doping purposes. Personal use by the holder does not satisfy it.

So the intuitive inference — "Luxembourg has an anti-doping law, therefore holding a GH peptide is a crime there" — is wrong. What is criminalised is supply-adjacent conduct, not possession.

We were not able to verify the Belgian penalty range under Article 2bis of the law of 24 February 1921, including the opdeciemen multiplier that Belgian fines carry. We are not printing a number we could not read from the statute.

There is also a Belgian structural point that catches people out: a product lawfully sold abroad as a supplement becomes a medicine on entry into Belgium if it contains a pharmacologically active substance. Classification does not travel with the product.

Enforcement: the regulators admit the limits

Evidence tier: 1 — agency statements.

The Belgian medicines agency concedes the whack-a-mole problem directly: it can take down `.be` domains, and beyond that its reach is limited. The Slovenian regulator put the same point more bluntly in a statement we quote in the Central & Eastern Europe guide — where sites are registered abroad with false data and rotate domains, the operators cannot be identified or sanctioned.

The practical consequence is worth stating plainly, because it cuts against the usual assumption. The realistic legal exposure falls on the domestic seller or reseller — including a private individual reselling on classifieds or social media — not on the offshore website. The site is beyond reach. The person in the country is not.

What we could not verify

• Whether Belgium's GLP-1 prescribing restriction was extended past 30 November 2025. This is the most consequential open item on the page.
• Belgium's 1 February 2026 prior-authorisation requirement — reported, not confirmed against the instrument.
• Belgian penalty ranges under the 1921 law, including the opdeciemen multiplier.
• RIZIV/INAMI reimbursement criteria for the diabetes GLP-1s and Saxenda — the pages are JavaScript-rendered.
• Luxembourg reimbursement of any GLP-1 through the CNS. We found nothing at all.
• Luxembourg's law of 11 January 1989 on substances with therapeutic activity, and whether it creates a Belgian-style regime for peptide raw materials.
• Personal import quantity limits for all three countries, expressed as consistent by-post vs hand-carried figures. Belgium and the Netherlands publish the seizure step; disposal practice is documented only in Belgium.
• Telehealth prescribing beyond the Dutch position and Belgian deontological guidance.

Limitations

This is educational content. It is not legal advice, and it is not medical advice.

• The Belgian prescribing restriction may or may not still be in force. Do not plan around it in either direction without checking.
• We describe what is lawful, not what to do. Nothing here is guidance on obtaining unapproved medicines, and we name no vendors or routes.
• Reimbursement decisions move quickly and several here are under a year old.
• We make no claim about the contents of the Dutch Dopinglijst or the Luxembourg Council of Europe annex — neither was opened.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Benelux is the region where the action is on the prescribing side rather than the border. Belgium reached for an instrument nobody else used — a Royal Decree specifying who may write the first GLP-1 prescription — and then added a prior-authorisation layer on top of reimbursement. Whether the first of those is still in force is genuinely unclear, and it matters more to a Belgian reader than any import rule.

The Dutch reimbursement position is the one most often stated wrongly online: liraglutide yes, under tight conditions; semaglutide no, refused in 2024 and still unassessed two years later.

And on doping law, Benelux sits opposite Scandinavia. Nobody here criminalises personal possession. Luxembourg's offence in particular requires that the substance be meant for someone else, which is narrower than the reputation of anti-doping law would suggest.

Related on this site

• Peptides in the Nordics: import rules and doping law
• Peptides in the Baltics: three different import rules
• Peptides in Central & Eastern Europe
• Are peptides legal in the European Union?
• What peptides are available in the EU
• Research-grade vs pharmaceutical-grade vs compounded peptides

References

• Netherlands, reimbursement: Regeling zorgverzekering, Annex 2 conditions for liraglutide — failed combined lifestyle intervention after one year, BMI ≥35 with comorbidity or ≥40, discontinuation at three months below 5% loss. Wegovy refused July 2024, unassessed as at 21 July 2026.
• Netherlands, enforcement position: Inspectie Gezondheidszorg en Jeugd (IGJ) statement of 16 April 2026 on research-use disclaimers.
• Belgium, prescribing restriction: Royal Decree requiring specialist initiation of GLP-1 treatment and prohibiting officinal preparations containing semaglutide and tirzepatide; reported to have lapsed 30 November 2025 — status unverified.
• Belgium, obesity reimbursement: Ministerial decision of 3 June 2026 following negative CTG advice on Wegovy, expressly citing the Dutch, German, Norwegian and Danish positions.
• Belgium, classification: a product lawfully sold abroad as a food supplement is treated as a medicine on entry where it contains a pharmacologically active substance.
• Luxembourg, doping offence: loi du 3 août 2005, art. 16 — requires both third-party purpose and knowledge of sporting doping use.
• Belgium, penalties: loi du 24 février 1921, art. 2bis — range and opdeciemen multiplier not verified; consult the consolidated text on Justel before relying on any figure.